Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1-Reference-Cited by-同舟云学术

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1

Published:2017-02-02 Issue:25 Volume:8 Page:41572-41581
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wang Lingzhi¹²,Linus Chan Chong En¹³,Wong Andrea Li-Ann¹⁴,Wong Fang Cheng¹,Lim Siew Woon³⁴,Chinnathambi Arunachalam⁵,Alharbi Sulaiman Ali⁵,Lee Lawrence Soon-U²,Soo Ross¹⁴,Yong Wei Peng¹⁴,Lee Soo Chin¹⁴,Ho Paul Chi-Lui³,Sethi Gautam²⁵⁶,Goh Boon Cher¹²⁴

Affiliation:

1. Cancer Science Institute of Singapore, National University of Singapore, Singapore

2. Department of Pharmacology, National University Health System, Singapore

3. Department of Pharmacy, National University of Singapore, Singapore

4. Department of Haematology-Oncology, National University Health System, Singapore

5. Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia

6. School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth WA, Australia

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial;Nature Communications;2024-08-07

2. Anticancer clinical efficiency and stochastic mechanisms of belinostat;Biomedicine & Pharmacotherapy;2023-09

3. Epigenetic modulations in cancer: predictive biomarkers and potential targets for overcoming the resistance to topoisomerase I inhibitors;Annals of Medicine;2023-04-24

4. “Domain Directional Optimization” strategy for the development of UGT1A1-activated fluorescent probe and the application in living systems;Sensors and Actuators B: Chemical;2022-10

5. An updated review on the potential antineoplastic actions of oleuropein;Phytotherapy Research;2021-11-22